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MOLECULAR CARCINOGENESIS
Genome-Wide DNA Methylation Analysis Identiﬁes
MEGF10 as a Novel Epigenetically Repressed Candidate
Tumor Suppressor Gene in Neuroblastoma
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Neuroblastoma is a childhood cancer in which many children still have poor outcomes, emphasising the need to better
understand its pathogenesis. Despite recent genome-wide mutation analyses, many primary neuroblastomas do not
contain recognizable driver mutations, implicating alternate molecular pathologies such as epigenetic alterations. To
discover genes that become epigenetically deregulated during neuroblastoma tumorigenesis, we took the novel approach
of comparing neuroblastomas to neural crest precursor cells, using genome-wide DNAmethylation analysis.We identiﬁed
93 genes that were signiﬁcantly differentially methylated of which 26 (28%) were hypermethylated and 67 (72%) were
hypomethylated. Concentrating on hypermethylated genes to identify candidate tumor suppressor loci, we found the cell
engulfment and adhesion factor geneMEGF10 to be epigenetically repressed by DNA hypermethylation or by H3K27/K9
methylation in neuroblastoma cell lines. MEGF10 showed signiﬁcantly down-regulated expression in neuroblastoma
tumor samples; furthermore patients with the lowest-expressing tumors had reduced relapse-free survival. Our functional
studies showed that knock-down of MEGF10 expression in neuroblastoma cell lines promoted cell growth, consistent
with MEGF10 acting as a clinically relevant, epigenetically deregulated neuroblastoma tumor suppressor gene. © 2016
The Authors. Molecular Carcinogenesis Published by Wiley Periodicals, Inc.
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INTRODUCTION
Neuroblastoma, one of the commonest solid
tumors of childhood, is an embryonal malignancy
that arises via defective differentiation of neural crest
cells that give rise to the sympathetic nervous system
[1,2]. Neuroblastoma patients have a poor outcome
compared to many other childhood cancer sufferers
[2], mostly attributable to older children who present
with metastatic disease [2,3].
Compared to other cancers, neuroblastomas dem-
onstrate relatively fewmutations [4–6], althoughcopy-
number changes are common, for example, loss of
chromosomes 1p and 11q and gain of 17q [2,3].
Oncogene activation occurs byMYCN amplification in
high-risk neuroblastomas [7] and by ALK mutation
in familial neuroblastoma and in about 10% of
sporadic cases [8–10]. Tumor suppressor genes found
infrequently mutated in neuroblastoma include
PHOX2B and NF1 [11,12]. Genomic sequencing of
neuroblastomas has identified additional mutated
genes such as the chromatin remodeling genes
ATRX, ARID1A, and ARID1B, components of the
RAC-RHO pathway [4–6] and rearrangements activat-
ing the TERT gene [13,14]. Relapsed neuroblastomas
demonstrate increased numbers of mutations during
disease progression [15,16].
The lack of identified driver genetic mutations in
many cases of neuroblastoma [1] underlines the need
to evaluate alternative mechanisms of pathogenesis,
including epigenetic aberrations such as DNA meth-
ylation [17], which constitute some of the earliest
changes in carcinogenesis [18].
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chromatin immunoprecipitation; PRC, polycomb repressive complex;
NB, neuroblastoma.
[This article was modified on 3 January 2017 after initial online
publication to correct the affiliation of Carmel McConville.]
Present address for the author Jessica Charlet is Bayer—North
American Headquarters, 100 Bayer Blvd, Hanover, NJ 07981, USA.
Grant sponsor: Fonds National de la Recherche Luxembourg (FNR);
Grant sponsor: CLIC Sargent UK; Grant number: C20791/A12743;
Grant sponsor: Cancer Research UK; Grant sponsor: John James Bristol
Foundation; Grant sponsor: University of Bristol Cancer Research Fund;
Grant sponsor: Institut National de la Sante et de la Recherche Medicale
(INSERM); Grant sponsor: Government of Saudi Arabia
*Correspondence to: School of Cellular and Molecular Medicine,
University of Bristol, Biomedical Sciences Building, University Walk,
Bristol, Bristol BS8 1TD, UK.
Received 29 July 2016; Revised 3 November 2016; Accepted 11
November 2016
DOI 10.1002/mc.22591
Published online in Wiley Online Library
(wileyonlinelibrary.com).
 2016 THE AUTHORS. MOLECULAR CARCINOGENESIS PUBLISHED BY WILEY PERIODICALS, INC.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
Epigenetic deregulation has been shown to play
an important role in neuroblastoma pathogenesis,
silencingneuroblastoma suppressor genes by aberrant
promoter DNA hypermethylation, for example,
RASSF1A, CASP8, and DCR2 [19–22], or by aberrant
histone methylation, for example, CASZ1, CLU,
RUNX3, NGFR [23], and p14ARF [24]. DNA hyper-
methylation of both individual genes and multiple
CpG islands has been associated with poor outcome
in neuroblastoma [20,21,25–27].
Despite previous gene-specific analyses of DNA
methylation (as discussed above) and more recent
genome-wide analyses [28–34], it remains unclear
which epigenetic alterations are critical for neuro-
blastoma pathogenesis and what functional roles
are played by the affected genes. To address this
question, we have taken a novel epigenomic
approach, using genome-wide DNA methylation
analysis to compare neuroblastoma cells to their
putative normal precursors, human neural crest cells
(hNCC). We have identified a series of genes that are
differentially methylated in neuroblastoma cells
compared to normal human neural crest cells. One
of these genes is MEGF10, for which we demonstrate
growth-repressive properties predicted for a tumor
suppressor gene.
MATERIALS AND METHODS
Cell Culture and Neuroblastoma Tumor Samples
Cell lines were obtained from ECACC, apart from
BCH-N-DW, which is a novel neuroblastoma cell line
derived from a bone marrow biopsy (Table S1; C.
McConville, unpublisheddata), SHEPTet-21/Nwhich
was a kind gift from Prof. M. Schwab, and SK-N-AS
MYCN-ERwhichwas a kind gift from Prof. A Sala. Cell
lines except SHEP Tet-21/N and SK-N-AS MYCN-ER
were cultured in DMEM/F12-HAM medium (Sigma,
Gillingham, Dorset, UK) supplemented with 10%
fetal bovine serum (FBS), 100U/ml penicillin,
0.1mg/ml streptomycin, 2mM L-glutamine, and 1%
non-essential amino acids (Sigma) at 378C in a 5%
CO2 incubator. SH-EP TET-21/N cells [35] were
cultured in RPMI1640 medium (Invitrogen, Paisley,
UK) containing 10% tetracycline-free FBS (Bioclear,
Calne, Wiltshire, UK), with other additives as
above and for MYCN silencing 1mg/ml tetracycline
(Sigma) was added. SK-N-AS MYCN-ER cells [36] were
cultured in DMEM/F12 containing 10% charcoal-
stripped FBS (Appleton Woods, Birmingham, UK)
with other additives as above and for MYCN induc-
tion 400nM 4-hydroxytamoxifen (Sigma) was
added. Neural crest cells were cultured as described
previously [37].
Neuroblastoma tumor samples (Table S2) were
obtained from Bristol and Birmingham Children’s
hospitals with appropriate local ethical approval
and used as specified in the UK Human Tissue
Act.
5-Aza-20-Deoxycytidine, 3-Deazaneplanocin A, GSK343,
and UNC0638 Treatment
Cell lines were incubated in medium containing
2mM 5-aza-20-deoxycytidine (azadC; Sigma) plus or
minus 0.1mM trichostatin A (TSA; Sigma), or
0.5mM—5mM 3-deazaneplanocin (DZNep; Cayman,
Cambridge Bioscience, Cambridge, UK) plus 0.1mM
TSA, or 10mM GSK343 (Selleckchem.com; Stratech
Scientific, Newmarket, UK) plus 0.1mM TSA, or
0.1mM UNC0638 (Sigma) plus 0.1mM TSA for up to
6d, with amedium change every 2 d. Control cultures
received equivalent volumes of drug solvent (DMSO).
DNA Extraction and Methyl CpG Immunoprecipitation (MCIP)
An outline of the MCIP workflow is shown in
supplementary Figure S1. DNA was extracted with a
DNeasy kit (Qiagen, Manchester, UK). MCIP was
performed as described in [38] and validated by
analysing fractions for their methylated DNA content
relative to input by QPCR (QuantiTect SYBR Green;
Qiagen), using the following control genes: WISP3
(hypermethylated), SNRPN (imprinted; 50% methyl-
ated), and TBP (unmethylated). Primer sequences are
given in Table S4 and validation results in Figure S2.
Methylation-enriched DNA fractions were co-hybrid-
ized with input DNA on to Human DNAMethylation
385K Promoter Plus CpG Island Arrays (NimbleGen;
Roche, Burgess Hill, Sussex, UK). Statistical analyses
employed ChIPMonk software (www.bioinformatics.
bbsrc.ac.uk/projects/chipmonk), using windowed
T-tests to identify differentially methylated probes
(Figure S1). log2 genemethylation levels were derived
from the mean probe ratios within 700bp of the
transcriptional start site (Table S3). The data discussed
in this publication have been deposited in NCBI’s
Gene Expression Omnibus [39] and are accessible
through GEO Series accession number GSE71958
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc =GSE71958).
Pyrosequencing
DNA was bisulfite converted (EZ DNA Methylation
Gold kit; Zymo Research; Cambridge Bioscience,
Cambridge, UK), amplified with biotinylated primers
(Qiagen) using a Pyromark PCR kit (Qiagen) and pyro-
sequencedonaPyroMarkQ96 instrument (Qiagen).The
two assays used for MEGF10 were Hs-MEGF10-01-PM
(sequence analyzed TCGATCGTGAGTCGCCCCTGC-
CTGAGCGGCTTCCACCGT) and Hs-MEGF10-02-PM
(sequence analyzed ACGCGGTTAGCGTYCAAGCA-
GCGT); both from Qiagen (Figure 3B).
Chromatin Immunoprecipitation (ChIP)
SHIN cells were fixed in 1% paraformaldehyde for
5min at room temperature, lyzed, sonicated and the
chromatin immunoprecipitated with rabbit anti-
H3K27me3 (Millipore #17-682, Millipore, Watford,
UK), mouse anti-H3K9me2 (Abcam ab1220, Abcam,
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Cambridge, UK), or normal rabbit or mouse IgG as a
control, using a Magna ChIP G kit (Millipore).
Enriched DNA was quantitated by real-time PCR
(QuantiTect SYBR Green; Qiagen) using primers for
GAPDH and MEGF10 (Table S4 and Figure S2C).
MEGF10 Transient Silencing
Cells were transfected with 50nM of siRNA against
MEGF10 (ON-TARGET plus SMART pool; Thermo
Scientific L-014897-01, Thermo Fisher, Hemel Hemp-
stead, UK) or a non-targeting pool (ON-TARGET plus
Non-targeting Pool; Thermo Scientific D-001810-10),
using DUO transfection reagent (Dharmacon, Little
Chalfont, Buckinghamshire, UK) and harvested after
72h.
RNA Extraction, cDNA Synthesis, and RT-PCR
Total RNA was extracted with an RNeasy kit
(Qiagen), DNase treated with TURBO DNA-free
(Ambion, Thermo Fisher, Hemel Hempstead, UK)
and cDNA synthesized using the Thermoscript
RT-PCR system (Invitrogen). Gene-specific primers
(Table S4) were used for end-point PCR, or QPCR
(QuantiTect SYBR Green; Qiagen) on an MX3000P
real-time PCR machine (Stratagene, Cambridge,
UK), normalising the amount of target gene to the
endogenous level of TBP. Human universal RNA
(Agilent, Stockport, Cheshire, UK) was used as a
reference to standardize results between QPCR
batches.
Protein Extraction and Western Blotting
Cultured cells were washed with ice-cold PBS and
lyzed in cell lysis buffer (Cell Signaling, New England
Biolabs, Hitchin, Hertfordshire, UK), with complete
mini inhibitors (Roche, Burgess Hill, Sussex, UK) for
10min on ice, and then sonicated for 5min at high
intermittent pulses (30/30) (Diagenode, Bioruptor,
Oxford, UK). Neuroblastoma tumor samples were
homogenized in cell lysis buffer, then processed as
for cultured cells. Samples were centrifuged for 10min
at10000gat48Cto removeanycelldebris and typically
25mg proteins were separated on a SDS–polyacryl-
amide gel and analyzed by Western blotting. Fetal
adrenal proteinwas fromBiochain. Primary antibodies
were against MEGF10 (rabbit, Sigma HPA026876) and
b-ACTIN (rabbit, AbcamAB8227), followed by second-
ary HRP-labelled anti-rabbit (Sigma A6154). Chemilu-
minescence detection was with ECLþ (GE Healthcare,
Little Chalfont, Buckinghamshire, UK) andX-ray films
were imaged on a flatbed scanner and analyzed using
Image J (http://imagej.nih.gov/ij/).
RESULTS
Genome-Wide DNA Methylation Analysis
To detect genome-wide DNA methylation alter-
ations in neuroblastoma, we usedMCIP and promoter
plus CpG island microarrays (Figure S1) [38,40] to
compare four neuroblastoma cell lines (Table S1) with
cultured human neural crest cells (hNCC [37]).
The primary data set of all probe ratios from the
microarray (see dendrogram in Figure 1A) suggested
that hNCC were distinct from all other cells but most
closely related to the I-type SK-N-AS cell line. The
three cell lines carrying oncogenemutations clustered
together, with the MYCN amplified BE(2)-C and
IMR32 being most closely related, while SHSY-5Y,
the only cell line carrying an ALKmutation [41], was
less related to the other two (Figure 1A).
Analysis of the DNA methylated genes detected by
MCIP (Table S3) showed both MYCN-amplified and
non-amplified cell lines had more methylated genes
than hNCC (Figure 1B). However, 83% of the genes
that were methylated in hNCC were also methylated
in the neuroblastoma cell lines and these genes
showed a similar gene ontology profile to other genes
that were methylated in the neuroblastoma cell lines,
but distinct from the pattern in hNCC (Figure 1C,
Table S5). This suggests that while part of the
neuroblastoma epigenome bears close similarity to
hNCC, presumably reflecting common developmen-
tal origins, there are also a distinct set of pathogenic
epigenetic changes in neuroblastoma.
Identification of Differentially Methylated Genes
We used windowed T-tests to identify genes that
showed significant hypermethylation or hypomethy-
lation in neuroblastoma cell lines compared to hNCC
(Figure S1, Table S6). About 93 genes were signifi-
cantly differently methylated between all four neuro-
blastoma cell lines andhNCC, ofwhich 26 (28%)were
hypermethylated and 67 (72%)were hypomethylated
(Table S6). The hypermethylated genes were enriched
in high-CpG and intermediate-CpG promoters (Table
S6; Figure 1D), whereas the hypomethylated genes
were enriched in low-CpG promoters (LCP; Table S6)
[42].
Using publicly available microarray data
(GSE19274) we found no direct correlation between
gene expression and DNA methylation; however,
across the four cell lines, the most highly expressed
genes weremostly hypomethylated; 96% of the genes
in the top 90% rank of expression were hypomethy-
lated (Figure S3; P¼0.002, Fisher exact test).
The chromosomal localization of the differentially
methylated genes showed no obvious clusters of
hyper- or hypomethylated genes (Figure S4).
The hypermethylated genes were significantly
enriched in genes involved in transcription and in
developmental processes, whereas the hypomethy-
lated genes were enriched for sensory perception,
signaling, and multicellular organism processes
(Table S7).
In agreement with previous reports [43–45], we
found that the hypermethylated genes were often
polycomb repressive complex (PRC) marked [46],
when compared to the hypomethylated genes
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Figure 1. Genome-wide DNA methylation analysis of neuroblas-
toma. (A) Dendrogram using Pearson's correlation coefﬁcient,
analysing all probe ratios from the MCIP/microarray analysis of
human neural crest cells (hNCC) and four neuroblastoma cell lines
(SK-N-AS, SHSY-5Y, IMR32, and BE(2)-C). MYCN ampliﬁcation, ALK
mutation, and neuroblastoma cell type are indicated next to the cell
line names. (B) Venn diagram of overlap between lists of methylated
genes having a probe ratio of greater than log2 0.5 (Table S3) found
in hNCC, MYCN-ampliﬁed, and non-ampliﬁed cell lines. (C) Gene
ontology proﬁles of the hNCC-unique methylated genes (hNCC),
genes shared between hNCC and neuroblastoma cell lines (shared),
and cell line-unique genes (NB). Full results shown in Table S5. (D)
Genes identiﬁed by MCIP as hypermethylated in four neuroblastoma
cell lines compared to hNCC. The ﬁrst ﬁve columns (“Gene
methylation”) are a heatmap of gene methylation values (blue¼ low,
red¼ high). CGI properties: PRC shows genes that are polycomb
marked in ES cells, HCP, ICP, and LCP deﬁne which promoters have
high, intermediate, or low CpG content. For quantitative DNA
methylation results and further explanation of PRC, HCP, ICP, and
LCP, see Table S6. NB data: “Survival” shows genes whose decreased
expression is signiﬁcantly associated with reduced relapse-free
survival in neuroblastoma (P< 0.05, log rank test); data generated
in R2 using GSE16476; and “Expression” shows genes whose RNA
expression is decreased in both neuroblastoma cell lines (GSE28019)
and neuroblastoma tumors (GSE16476) compared to neural crest
cells (GSE14340); comparison was made using the “Megasampler”
function in R2 Genomics Analysis and Visualization Platform (http://
r2.amc.nl). See Table S8 for full results.
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(Figure 1D and Table S6; P¼1.37106; Fisher exact
test).
Thus, MCIP identified a set of genes that were
differentially methylated between hNCC and neuro-
blastoma, which are excellent candidates for genes
that play a significant role in neuroblastoma patho-
genesis via epigenetic deregulation.
Selection of Candidate Tumor Suppressor Genes
Initially, we concentrated on hypermethylated
genes, to identify novel epigenetically repressed tumor
suppressor genes. We used publicly available data to
screen all 26 hypermethylated genes for their possible
involvement in neuroblastoma pathogenesis by ex-
amining (i) the association between RNA expression
and relapse-free survival; and (ii) RNA expression in
neuroblastoma tumors and cell lines compared to
neural crest (Figure 1D, Table S8). Seven genes showed
poorer survival in low-expressing tumors and seven
showed decreased RNA expression both in cell lines
and tumors compared to neural crest; however, only
one gene,MEFGF10, had aneffect on survival aswell as
decreased expression in neuroblastoma (Figure 1D).
We confirmed the consistent silencing of MEGF10 in
all four neuroblastoma cell lines by end-point PCR
(Figure S5).We therefore went on to examineMEGF10
expression in tumors and its potential biological
function in neuroblastoma.
Expression and Biological Function of MEGF10
QPCR analysis of neuroblastoma tumors and cell
lines showed significantly lowerMEGF10 RNA expres-
sion than in normal tissues (Figures 2A and S6). Our
RNA expression results were replicated in publicly
available expression microarray datasets (Figure 2B)
and importantly, thesemicroarray data demonstrated
a significant association between low-MEGF10 ex-
pression and reduced relapse-free survival in neuro-
blastoma patients, especially inMYCN non-amplified
tumors (Figure 2C).
Western blotting analysis of MEGF10 protein
expression (Figure 2D) showed that 87% (20 out of
23) of neuroblastomas had lower MEGF10 protein
levels than that found in fetal adrenal (Figure 2E), in
agreement with the RNA expression data (Figure 2A).
This suggests that MEGF10 expression is primarily
controlled at the transcriptional level.
MEGF10 knockdown effectively reduced RNA and
protein expression in the highly expressing neuro-
blastoma cell line GIMEN and caused a reproducible
three- to fourfold increase in cell numbers at 72h
(Figure 2F). This result was replicated in a second cell
line, BCH-N-DW (Figure S7).
These results suggest that MEGF10 may have an
important role in regulating neuroblastoma growth,
although further in vitro and in vivo experiments are
required to understand the significant of these
preliminary functional analyses. The consistent tran-
scriptional down-regulation ofMEGF10 expression in
both neuroblastoma tumors and cell lines led us
to carry out a detailed analysis of the epigenetic
regulation of MEGF10 in neuroblastoma.
DNA Methylation of MEGF10 in Neuroblastoma
We examined DNA methylation by pyrosequenc-
ing at two sites in theMEGF10CpG island in 6 normal
tissues, 9 neuroblastoma cell lines, and 46 neuroblas-
toma tumor samples (Figure 3A and B). The pyrose-
quencing assays overlappedwith the region identified
as methylated in the MEGF10 gene by our MCIP/
microarray analysis (Figure S2C).
In the neuroblastoma cell lines there was no apparent
relationship between the cell types (I, N, S) and their
MEGF10 expressionormethylation,norbetweenMYCN
amplification andMEGF10DNAmethylation or expres-
sion (Figure 3C). In two inducible MYCN expression
systems we found no reproducible change in DNA
methylationwhenMYCN expressionwas altered (Figure
S8), in agreement with our previous findings [47].
Of thenineneuroblastomacell lines, sevenexpressed
reduced levels of MEGF10 RNA compared to normal
tissues (fetal adrenal and hNCC) and most had some
degree of DNA hypermethylation, while two cell lines
(GIMEN and BCH-N-DW), had MEGF10 RNA expres-
sion levels comparable to normal tissues and these two
cell lines were unmethylated (Figure 3C). Thus DNA
hypermethylationwas common in neuroblastoma cell
lines (Figure 3E) and there was an inverse relationship
between MEGF10 expression and DNA methylation
(Figure 3C; r2¼0.914), suggesting a possiblemechanis-
tic role for DNA methylation in regulating MEGF10
expression. This was confirmed by treating the hyper-
methylated lineSHSY-5Ywiththedemethylatingagent
5-aza-20-deoxycytidine (azadC), which increased
MEGF10 RNA expression 10-fold (Figure 3D).
We then investigated DNAmethylation ofMEGF10
in neuroblastoma tumor samples and found that only
4 of 46 (9%) had DNAmethylation levels higher than
normal tissues (Figure 3A and E). Interestingly, one of
these four tumors was stage 3 and three were stage 4,
suggesting that hypermethylation was associated
with more aggressive tumors. All four hypermethy-
lated tumors showed decreased overall survival
compared to the hypomethylated tumors (Figure
4F). We found no hypermethylation of MEGF10 in
other childhood cancers, including aggressive cancers
such as rhabdoid tumors (Figure S9), suggesting that
MEGF10 hypermethylation is restricted to some poor
prognosis neuroblastomas.
We have demonstrated that MEGF10 expression
is consistently down-regulated in neuroblastoma
(Figure 2A and B), and that DNA hypermethylation
appears to be prevalent in neuroblastoma cell
lines but confined to a small subset of aggressive
neuroblastoma primary tumor samples (Figure 3A
and E). We therefore investigated other plausible
epigenetic modifications that might repressMEGF10
in neuroblastoma.
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Figure 2. MEGF10 expression and biological function. (A)
MEGF10 RNA expression levels, investigated by QPCR in normal
tissues (NT, n¼ 5), neuroblastoma cell lines (n¼ 9), and neuroblas-
toma tumor tissue (NB, n¼ 25), normalized to the endogenous
levels of TBP and expressed relative to universal RNA (P< 0.05,
Mann–Whitney test). Full results are shown in Figure S6. (B)
MEGF10 RNA expression in normal adrenal (GSE3526, GSE7307,
GSE8514) and four different sets of neuroblastoma tumor tissue
(GSE16476, GSE12460, GSE16237, GSE13136), as measured using
Affymetrix U133 microarrays (data from R2). Neuroblastomas
showed signiﬁcantly lower expression compared to normal adrenal
(one-way ANOVA P¼ 8.9 107). (C) Relapse-free survival curve
taken from dataset GSE16476 for patients with tumors lacking
MYCN ampliﬁcation (data from R2). Low-expressing tumors showed
decreased relapse-free survival compared to high-expressing tumors
(P¼ 0.0014). (D) MEGF10 protein levels assayed by Western blot in
fetal adrenal (FA) and 23 neuroblastomas (NB) with ACTIN as
loading control. (E) Bar chart of MEGF10 protein levels relative to
ACTIN, expressed as a ratio of the level in fetal adrenal (FA). (F)
Growth of GIMEN neuroblastoma cells 72 h after transfection with
MEGF10 siRNAs (siMEGF10) or non-targeting pool (siNEG). Left-
hand panel: Western Blot of MEGF10 protein expression (represen-
tative of three experiments). Fetal brain is shown as a control tissue
expressing high levels of MEGF10. Middle panel: MEGF10 RNA
expression assayed by QPCR expressed relative to siNEG controls
(mean SEM of three experiments). Right-hand panel: Attached
cell counts expressed relative to siNEG controls (mean SEM of
three experiments, P< 0.05, paired t test).
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Figure 3. MEGF10 DNA methylation in neuroblastoma. (A) MEGF10
methylation assayed by pyrosequencing assays 01_PM (unﬁlled bars)
and 02_PM (black bars) in normal tissue (fetal muscle [FM], fetal kidney
[FK], normal kidney [NK], fetal lung [FL], humanneural crest cells [hNCC],
fetal adrenal [FA]), neuroblastoma cell lines and neuroblastoma tumors,
grouped by stage. (B) MEGF10 DNA methylation assayed by pyrose-
quencing assays 01_PM and 02_PM in hNCC and the four neuroblas-
toma cells lines used for MCIP. Bars show the percentagemethylation at
each CpG in the two pyrosequencing assays, positioned relative to the
MEGF10 ﬁrst exon and CpG island (CGI), using the UCSC genome
browser (http://genome.ucsc.edu). (C)MEGF10 RNA expression assayed
by QPCR (black bars) and DNA methylation levels detected by
pyrosequencing (unﬁlled bars), in control tissues and neuroblastoma
cell lines. RNA levels were normalized to the endogenous levels of TBP
and expressed relative to universal RNA (full data in Figure S6). DNA
methylation was calculated as the average of the 01_PM and 02_PM
pyrosequencing assays (A). Neuroblastoma subtypes (I, N, or S) and
MYCN ampliﬁcation status are shown above the cell line names. (D)
MEGF10 RNA expression in SHSY-5Y cells treated with 2mM azadC
(AZA) for 2–4d. RNA levelswere normalized to the endogenous levels of
TBPandexpressedas foldexpression relative to levels in controls (solvent-
treated). (E) BoxPlot of MEGF10 DNA methylation measured by
pyrosequencing in normal tissues (NT, n¼ 6), neuroblastoma cell lines
(n¼ 9), and neuroblastoma tumor tissue (NB, n¼ 46), using the average
of assays 01_PM and 02_PM; full results are shown in (A) (P< 0.005,
NS; not signiﬁcant, Mann–Whitney test). (F) Kaplan–Meier overall
survival curve taken from dataset of NB patients in (A) for whom survival
data were available. Me, tumors with no DNAmethylation compared
to fetal adrenal and neural crest; Meþ, tumors with increased DNA
methylation compared to fetal adrenal and neural crest (using the
average of assays 01_PM and 02_PM). Meþ tumors showed decreased
overall survival compared to Me, tumors (P¼ 0.0009; log rank test).
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MEGF10 Is Also Silenced by Repressive Histone Modifications
In order to identify other possible epigenetic mecha-
nisms thatmight explain the transcriptional repression
of MEGF10 in the majority of neuroblastomas, which
are not DNA methylated, we examined repressive
histone modifications using pharmacological inhib-
itors and ChIP.
In the cell line that had repressed MEGF10 expres-
sion with the lowest DNA methylation (SHIN;
Figure 3C), MEGF10 expression was poorly
stimulated by the DNA methylation inhibitor 5-aza-
Figure 4. Reactivation of MEGF10 expression and ChIP. (A) QPCR
of MEGF10 expression in SHIN and IMR32 cells treated with 0.5mM
DZNep plus 0.1mM TSA (gray bars) or 2mM azadC plus 0.1mM TSA
(black bars) for 6 d. The control treatment was solvent (DMSO)
(unﬁlled bars). RNA expression levels were normalized to the
endogenous levels of TBP and expressed relative to the untreated
controls (mean SEM of four experiments, P< 0.05, P< 0.005,
paired t test). (B) QPCR of MEGF10 expression in SHIN cells treated
with 5mM DZNep plus 0.1mM TSA (gray bar), 10mM GSK343 plus
0.1mM TSA (hatched bar) or 0.1mM UNC0638 plus 0.1mM TSA
(dotted bar) for 24 h. The control treatment was solvent (DMSO)
(unﬁlled bar). RNA expression levels were normalized to the
endogenous levels of TBP and expressed relative to the untreated
controls (mean SEM of four experiments, P< 0.05, P< 0.005,
paired t test). (C) Left-hand panel: H3K27me3 at the MEGF10
promoter (prom) or MEGF10 exon 1 (EX1), expressed as fold
enrichment compared to GAPDH, in control and DZNep plus TSA-
treated SHIN cells (mean SEM of three experiments, P< 0.05,
paired t test). Middle panel: H3K9me2 at the MEGF10 promoter
(prom) or MEGF10 exon 1 (EX1), expressed as fold enrichment
compared to GAPDH, in control and DZNep plus TSA-treated SHIN
cells (mean SEM of three experiments, P< 0.05, NS, not signiﬁ-
cant; paired t test). Right-hand panel: RNA expression of GAPDH and
MEGF10 in SHIN cells treated with 5mM DZNep plus 0.1mM TSA for
24 h. Results shown relative to untreated controls (mean SEM of six
experiments, P< 0.005, NS, not signiﬁcant; paired t test).
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20-deoxycytidine plus trichostatin A (azadCþTSA;
Figure 4A). However, 3-deazaneplanocin A, an agent
that inhibits repressive histone methylation marks
such as H3K27me3 and H3K9me2 [48], plus TSA
(DZNepþTSA), caused a substantial increase in
MEGF10 expression (Figure 4A). In contrast, in the
most highly DNAmethylated cell line (IMR32; Figure
3C), MEGF10 expression was reactivated by azadCþ
TSA; but not by DZNepþTSA (Figure 4A). To verify
the possible involvement of H3K27me3 and/or
H3K9me2, we treated SHIN cells with the specific
EZH2 inhibitor GSK343 [49], or with the specific G9a
and GLP inhibitor UNC0638, both of which also
caused reactivation ofMEGF10 expression (Figure 4B).
These results implicated the repressive histone
modifications H3K27me3 and H3K9me2 in the
epigenetic silencing of MEGF10.
We therefore went on to use chromatin immuno-
precipitation (ChIP) to directly test for H3K27me3
and H3K9me2 at MEGF10 in SHIN cells. At both
locations tested, MEGF10 had higher levels of
H3K27me3 than atGAPDH, a constitutively expressed
housekeeping gene (Figure 4C, left). There was also
increased H3K9me2 at the MEGF10 promoter region
(Figure 4C, middle). This pattern of a wide distribu-
tion of H3K27 marks but with H3K9 marks concen-
trated around the promoter region, agrees with the
general pattern of histone methylations observed for
silenced genes in the human genome [50]. Treatment
with DZNepþTSA increased expression of MEGF10
but notGAPDH (Figure 4C, right) and at the same time
decreased H3K27me3 and H3K9me2 at MEGF10
(Figure 4C, left and middle).
Thus, even in a cell linewhereMEGF10methylation
was low, MEGF10 expression was epigenetically
silenced but by repressive histone methylation,
suggesting that in non DNA-methylated neuroblasto-
mas, MEGF10 may still be epigenetically repressed.
DISCUSSION
This epigenomic study detected neuroblastoma-
specific DNA methylation changes by taking the novel
approach of comparing malignant neuroblastoma
cell lines with cultured normal neural crest cells
(hNCC), their putative precursors [1,2] (Figure S1).
Many neuroblastomas are thought to develop from
the sympathoadrenal lineage, which contributes to
the sympathetic ganglia and medullary region of the
adrenal gland. However, neuroblastomas can occur at
anypositionalong the sympathetic axis, suggesting that
they can also develop from earlier neural crest deriva-
tives [51]. Thus, we have used neural crest cells in our
experiments, as these probably represent the earliest
available common precursor for all neuroblastomas.
Overview of DNA Methylation Changes
The methylation levels of all probes from the array
(Figure 1A), together with the annotated genes
identified as methylated (Figure 1B and C), clearly
showed that neural crest cells and neuroblastoma
cells were related, reflecting their common develop-
mental origins [1]. However, there were a large
number of neuroblastoma-specific methylated genes
(Figure 1B), demonstrating that deregulated epige-
netic modifications play an important role in neuro-
blastoma pathogenesis.
Of the differentially methylated genes, 72% under-
went hypomethylation and 28% showed increased
methylation levels compared to hNCC (Table S6).
In MYCN amplified BE(2)-C and IMR32 cells, the
transcriptional activation power of MYCN, together
with induced chromatin changes leading to higher
gene activation levels [52,53], could explain the
increased hypomethylation, although another mech-
anism must be involved in the MYCN non-amplified
cell lines. Two recent genome-wide DNAmethylation
studies also reported a preponderance of DNA
hypomethylation in neuroblastoma [32,33], suggest-
ing that epigenetic gene activation may be more
common than repression in neuroblastoma. In this
article, we concentrated on hypermethylated genes,
in order to identify epigenetically repressed tumor
suppressors.
Characterization of the Hypermethylated Genes in
Neuroblastoma Cell Lines
Ourmethylation results are not directly comparable
with other studies, because we have made the novel
comparison of cultured neural crest cells with neuro-
blastoma cell lines, whereas most other studies have
made comparisons between different neuroblastoma
subtypes (e.g., low- vs. high-risk). However, some of
the hypermethylated genes that we have identified
have also been reported in other genome-wide studies
of DNA methylation in neuroblastoma; specifically
ADRA1A [33],CHAT [33], FAS [31],HOXD3 [29,32,33],
RAB38 [33], RNF220 [33], SLC17A6 [33], and TBX4
[33,54]. In addition, others have found hypermethyl-
ation at the HOXA cluster [28] and at the PCDH
clusters [31–34,55], where we found HOXA11 and
PCDHA9 hypermethylated (Figure 1D).
The shared hypermethylated genes in the four
neuroblastoma cell lines were enriched in high-CpG
promoters and PRC-marked genes (Figure 1D), as
expected from previous reports [42–45]. This suggests
thatmanyof thehypermethylated genes are normally
unmethylated but PRC-marked in stem cells and
undergo “instructive”methylation [56] to irreversibly
repress genes that drive differentiation during
development.
Gene ontology analysis showed that the hyper-
methylated hits that we detected were enriched in
genes involved in developmental processes (Table S7),
which are presumably targets that need to be silenced
in neuroblastoma in order to facilitate the develop-
mental arrest that is thought to be the primary cause
of childhood cancers [57].
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We carried out the genome-wide DNAmethylation
analysis using neuroblastoma cell lines, which we
compared to cultured neural crest cells, so that we
compared cultured cells in all cases, rather than
cultured cells versus primary tissue, to reduce differ-
ences in DNA methylation caused solely by cell
culture [58]. In addition, we used publicly available
expression data from primary tumors and associated
patient survival data to filter the DNA hypermethy-
lated genes, in order to identify candidate genes for
further study that had in vivo relevance. MEGF10
satisfied all our expression and survival criteria (Figure
1D), making it the obvious candidate for detailed
analysis.
Epigenetic Deregulation of MEGF10 in Neuroblastoma
All neuroblastoma cell lines, except the S-type
GIMEN and BCH-N-DW, had some degree of DNA
hypermethylation ofMEGF10 and very low or absent
expression (Figure 3C). There was an inverse relation-
ship between MEGF10 DNA methylation and expres-
sion (Figure 3C) andMEGF10 could be reactivated by
treating hypermethylated cells with the DNA deme-
thylating agent aza-deoxycytidine (Figures 3D and
4A), suggesting that DNA methylation plays a
mechanistic role in the control ofMEGF10 expression
in the majority of neuroblastoma cell lines. In the
SHIN cell line, where MEGF10 expression was
repressed but there was little DNA methylation
(Figure 3C), we demonstrated that MEGF10 was
transcriptionally silenced by repressive histone mod-
ifications (Figure 4).
MEGF10 expression was consistently down-regu-
lated in neuroblastoma tumor tissue compared to
normal tissue, as shown by our own results and by
those in publicly available datasets (Figure 2A and B).
Thus our genome-wide epigenetic analysis, based on
studying cultured cells, has correctly identified
MEGF10 as a repressed gene with direct relevance to
neuroblastoma in vivo. Genome-wide mutation
analyses of neuroblastomas have not identified
genetic abnormalities in MEGF10 [4–6] and there
was only infrequent (4/46; 7%) hypermethylation of
MEGF10 in tumor tissue (Figure 3A and E). It therefore
seems likely that MEGF10 expression is silenced in
most neuroblastomas by epigenetic mechanisms
other than DNA methylation, such as repressive
histone modifications H3K27me3 and/or H3K9me2,
as we have shown in the SHIN cell line (Figure 4), and
as has been reported for other neuroblastoma tumor
suppressor genes [23,24,55].
Interestingly, analysis of publicly available DNA
methylation data (GSE39626; [32]) gave similar
results to those reported in this paper, with 2/25
(9%) of neuroblastomas having MEGF10 DNA hyper-
methylation. Both of those MEGF10-hypermethyl-
ated tumors were high-risk [32] and in our data all
the hypermethylated tumors were stages 3 or 4, and
showed decreased overall survival (Figure 3F),
suggesting that MEGF10 DNA hypermethylation
occurs predominantly in an aggressive subset of
neuroblastomas. Most neuroblastoma cell lines are
derived from high-risk tumors [59] and we found the
majority of cell lines to be DNA hypermethylated at
MEGF10 (Fgure 3A–C). It therefore possible thatmany
neuroblastoma cell lines derive from a subpopulation
of cells within high-risk tumors that is hypermethy-
lated at MEGF10. Alternatively, DNA hypermethyla-
tion of MEGF10 in neuroblastoma cell lines may
represent a long-term stable epigenetic mark that
serves to “lock” the silenced state in a gene that is
normally repressed in neuroblastoma tumors by
histone modifications [60].
Functional Consequences of MEGF10 Repression
MEGF10 encodes a transmembrane protein with
multiple epidermal growth factor-like domains and
was initially thought to be mainly involved in the
engulfment of apoptotic cells [61,62]. MEGF10 is
strongly expressed in the neural tube during early
development, then in the spinal cord, CNS and
developingmuscle, with inheritedmutations causing
infantile mypoathies [63]. MEGF10 also mediates
cell–cell adhesion [64] and regulates retinal neuron
patterning via homophilic interactions [65], showing
that the gene plays a role in cellular interactions as
well as in apoptotic engulfment.
Our siRNA knock-down experiments (Figures 2F
and S7) demonstrated that reduced expression of
MEGF10 led to increased proliferation, suggesting
that MEGF10 plays a growth regulatory role in
neuroblastoma, potentially acting as a tumor sup-
pressor. Publicly available clinical data showed an
association between reducedMEGF10 expression and
decreased relapse-free survival in neuroblastoma
(Figure 2C), implying that the in vitro growth
regulatory effects may reflect clinically relevant
biological behavior. This effect was most pronounced
in MYCN non-amplified tumors (Figure 2C), suggest-
ing that in the context of MYCN amplification,
reduced MEGF10 expression does not have a signifi-
cant effect on neuroblastoma survival, presumably
because the multiple biological pathways related to
neuroblastoma aggressiveness that are targeted by
MYCN predominate [66]. Interestingly, altered ex-
pression ofMEGF10 has now been reported in several
cancers [67–69], with prognostic significance in
ovarian cancer [68] and glioblastoma [69].
MEGF10 is tyrosine phosphorylated and its phos-
phorylation can bemodulated by FGF [70], suggesting
a role in cellular signaling pathways. Functionally,
MEGF10 is implicated in Schwann cell plasticity [71]
and importantly, in the stemness of neuroblastoma
cells [72]. Our epigenetic studies have shown that
MEGF10 expression is frequently down-regulated in
neuroblastomas and that itmodulates neuroblastoma
growth properties. These findings suggest that
MEGF10 plays an important role in neuroblastoma
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biology and investigation of the mechanisms regulat-
ingMEGF10 and its involvement in cellular signaling
pathways may identify new therapeutic targets for
neuroblastoma, as well as prognostic markers.
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